Antiphospholipid Syndrome clinical trials at UC Health
2 in progress, 1 open to new patients
A Registry Study for Pediatric Patients With Antiphospholipid Syndrome (the immune system wrongly attacks normal blood proteins)
“This research study will take a look at Antiphospholipid Syndrome in order to learn how to better diagnose and control it.”
open to eligible people ages up to 18 years
The purpose of this study is to gather information about causes and treatment of Antiphospholipid Syndrome.
at UC Davis
Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome
Sorry, not currently recruiting here
ASTRO-APS is a prospective, randomized, open-label blinded endpoint pilot study among patients with a clinical diagnosis of the AntiPhospholipid Syndrome and are already taking an anticoagulant for the secondary prevention of thrombosis (blood clots). Subjects will be randomized to receive either warfarin (target INR range 2-3) or apixaban 5 mg twice daily. Patients will follow up with the study team for 13 months. 2 in-clinic follow-up visits will be performed as well as 4 telephone follow-up visits. Study participants will be asked to consent to follow up telephone calls and questionnaires at 3 month intervals following the completion of the study procedures for the main portion of the study.
at UC Davis
Last updated: